IL17A and psoriasis: Morita A et al. found that BD2 (beta-defensin 2) is a stable and easily measurable protein that has the potential to serve as a surrogate biomarker for monitoring responses to IL-17A-targeted therapies in clinical practice in a study conducted on 30 psoriasis patients.